[Study toward practical use of oligonucleotide therapeutics]

Area of Science:

• Pharmacology and Drug Development
• Molecular Biology and Genetics
• Regulatory Science

Background:

• Oligonucleotide therapeutics, including antisense oligonucleotides and small interfering RNAs (siRNAs), have seen significant development over the past decade.
• The FDA approval of mipomersen highlights the therapeutic potential of oligonucleotide-based drugs.
• Current methods for evaluating the quality, efficacy, and safety of these therapeutics are not fully established, and specific regulatory guidance is lacking.

Purpose of the Study:

• To address the lack of standardized evaluation methods and regulatory guidance for oligonucleotide therapeutics.
• To propose potential designs for quality evaluation and preclinical safety assessment of oligonucleotide-based drugs.
• To foster collaboration between academic institutions (Osaka University) and regulatory bodies (PMDA) in advancing regulatory science for novel therapeutics.

Main Methods:

• Collaborative discussion and analysis involving experts from Osaka University and the Pharmaceuticals and Medical Devices Agency (PMDA).
• Review of existing knowledge and identification of gaps in quality and safety evaluation methodologies for oligonucleotide therapeutics.
• Development of proposed frameworks for preclinical safety and quality assessment tailored to oligonucleotide-based drugs.

Main Results:

• Identification of critical areas requiring standardized quality control measures for oligonucleotide therapeutics.
• Proposal of a framework for preclinical safety evaluation, considering the unique characteristics of oligonucleotide drugs.
• Highlighting the need for specific regulatory guidance to ensure the safe and effective development of oligonucleotide-based medicines.

Conclusions:

• Standardized quality and preclinical safety evaluation methods are crucial for the advancement of oligonucleotide therapeutics.
• Collaborative efforts between researchers and regulatory agencies are essential for establishing robust regulatory science.
• The proposed evaluation designs aim to support the development and approval of novel oligonucleotide-based treatments.